United States: The Long-Awaited 340B Drug Pricing Program Omnibus Guidance: Part IV

Last Updated: October 14 2015
Article by Kathleen A. Reed

Duplicate Discounting, Recordkeeping, Audit and Repayment

This is the fourth and final in a series of updates addressing the 340B Drug Pricing Program Omnibus Guidance published by the Health Resources and Services Administration (HRSA) on August 28, 2015 (Guidance). The proposed Guidance clarifies various aspects of covered entity and drug manufacturer compliance with Section 340B of the Public Health Service Act (PHSA), topics that are currently addressed in a number of HRSA guidance documents published in the Federal Register dating back to 1992. This update addresses issues of duplicate discounting, recordkeeping, audit and repayment matters under the 340B Drug Pricing Program (340B Program).

Duplicate Discounting

In addition to the discounting required under the 340B Program, the Social Security Act also requires drug manufacturers to provide a rebate to a state for a covered outpatient drug provided to a Medicaid fee-for-service (FFS) or Medicaid managed care organization (MCO) patient. In order to prevent duplicate discounting under both the 340B Program and the Medicaid rebate, HHS has created the Medicaid Exclusion File. Upon enrolling in the 340B Program, a Covered Entity must notify HHS as to whether it will purchase and dispense 340B Covered Drugs to its Medicaid patients ("carve in") or will not use 340B discounted drugs to dispense to its Medicaid patients ("carve out"). A Covered Entity that opts to carve in will have its NPI and/or Medicaid billing number listed in the Medicaid Exclusion File, providing states with a mechanism for determining which outpatient drug dispensing events are eligible for a Medicaid rebate, and which are not. A Covered Entity may make different carve in/carve out status decisions with regard to its FFS Medicaid patients than it makes for its MCO Medicaid patients. Further, a Covered Entity may also make different carve in/carve out decisions by Covered Entity site and by MCO. However, the Covered Entity must provide HHS with specific information identifying each site and MCO for inclusion in the Medicaid Exclusion File. A Covered Entity may notify HHS of a change in its carve in/carve out status at any time, but the decision becomes effective only on a quarterly basis.

Recordkeeping

The PHSA requires Covered Entities to allow HHS and certain manufacturers to audit the Covered Entity's records that pertain to compliance with 340B Program requirements. Because maintenance of auditable records is a condition of eligibility for the 340B Program, failure to maintain such records can result in termination of the Covered Entity from the 340B Program. However, the Guidance states that HHS will use discretion when terminating for record keeping failures, and will not necessarily terminate if the Covered Entity's non-compliance is not systemic. For example, a Covered Entity that generally keeps auditable records but is unable to produce records regarding a specific instance of dispensing will not be terminated from the 340B Program, but would be presumed to have diverted the drug for which there is no record, and would be liable for repayment. In addition to termination, a systemic failure of recordkeeping could also subject a Covered Entity to repayment for all time periods during which auditable records were not maintained. HHS will provide a Covered Entity with notice and an opportunity for a hearing prior to termination for ineligibility due to lack of recordkeeping. A dis-enrolled Covered Entity is permitted to re-enroll at the next regular enrollment period at which it can demonstrate compliance with the auditable recordkeeping requirement.

Interestingly, the Guidance does not contain specific requirements for the form or content of the required auditable records. We recommend that a Covered Entity insure that its records can demonstrate compliance with all of the requirements applicable to the Covered Entity set forth in the Guidance. The Guidance also requires that records be maintained with regard to all child sites and Contract Pharmacies, and proposes that they be maintained for not less than five years. For terminated Covered Entities, records must be maintained for five years after the date of termination.

Audits

Covered Entity Audits

While the Guidance recommends that Covered Entities undertake regular audits of their compliance with 340B Program requirements, it does not dictate who must audit (internal or external), how often audits must occur, or the content of a such audits, except when the audit pertains to a Contract Pharmacy. In contrast to past HRSA guidelines, the Guidance now specifically recommends that Covered Entities conduct annual audits of their Contract Pharmacies undertaken by independent auditors. Further, as a separate compliance mechanism, the Covered Entity should perform comparisons of the 340B drugs dispensed by a Contract Pharmacy against the Covered Entity's 340B prescribing records on a quarterly basis. The Guidance instructs Covered Entities to correct any instances of duplicate discounts or diversion discovered during annual audits or quarterly reviews, and report the corrective action to HHS.

HHS Audits

The PHSA also gives HHS authority to audit Covered Entities and drug manufacturers to check for compliance with 340B Program requirements (this update will focus only on HHS audits of Covered Entities, not manufacturers). A Covered Entity that does not give HHS access to all records pertaining to its compliance, including records of child sites and Contract Pharmacies, may be terminated from the 340B Program. HHS is limited to conducting only one audit per Covered Entity at any given time, and is obligated to minimize disruptions to the Covered Entity while conducting the audit. HHS may audit for compliance with 340B Program requirements, satisfaction of enrollment and eligibility requirements, as well as the accuracy of the information in the 340B data base, and may perform its audits on- or off-site.

New under the Guidance, HHS is proposing a notice and hearing process that will give Covered Entities the opportunity to respond to adverse HHS audit findings, "other instances of noncompliance" and proposed loss of 340B Program eligibility. The notice and hearing process will be conducted "on the record" based on documents timely submitted by the Covered Entity in response to a notice from HHS detailing the alleged noncompliance. A Covered Entity's failure to respond to an HHS notice within 30 days, or to obtain an extension, will constitute the Covered Entity's agreement with the noncompliance alleged in the HHS notice. HHS will review the Covered Entity's timely submissions and make a final determination that may require a corrective action plan by the Covered Entity or may result in termination from the 340B Program. The Guidance indicates that HHS will work with Covered Entities to determine a timeline for submitting a corrective action plan. HHS characterizes the corrective action plan and all documentation of its implementation as auditable records that must be maintained by the Covered Entity as such.

Manufacturer Audits

The PHSA authorizes a drug manufacturer to audit a Covered Entity's compliance with statutory prohibitions against duplicate discounts and diversion of 340B Covered Drugs. A manufacturer is not permitted to audit a Covered Entity's compliance with 340B Program eligibility requirements. Before it may conduct an audit, a manufacturer must establish, to HHS's satisfaction, that a "reasonable cause" exists to conclude that a Covered Entity has violated the diversion or duplicate discount prohibitions. The Guidance provides examples of what facts or evidence may constitute reasonable cause, which may include a Covered Entity's failure to respond to a manufacturer's questions regarding diversion and duplicate discounts. Additionally, a manufacturer must develop an audit work plan with HHS to insure that its audit is limited to permitted issues. The Guidance explains the standards which apply to manufacturer audits, including use of an independent certified accounting firm to perform the audit in accordance with government auditing standards, and limiting the duration of an audit to one year. The Covered Entity is required, under PHSA, to provide records necessary to conduct the audit as a condition of its eligibility for the 340B Program. At the end of the audit, the independent auditor submits a final audit report to HHS for action.

Repayment

The PHSA makes a Covered Entity liable to the manufacturer for any discount improperly obtained as a result of diversion (dispensing to ineligible patients), duplicate discounts (using 340B drugs for Medicaid patients for whom the state also receives a rebate) or ineligibility of the entity to participate in the 340B Program. This liability also runs to diversion and duplicate discounting that occurs at a Contract Pharmacy. The Guidance instructs Covered Entities and manufacturers to work together regarding repayment (and refunds) within 90 days of identifying a violation (or overcharge). The manufacturer retains discretion regarding whether or not to request repayment based on business considerations, provided the manufacturer complies with applicable law, including the federal anti-kickback statute, in exercising that discretion. Some manufacturers may decide not to accept repayments below a certain minimum threshold amount, or to use a credit/rebill mechanism to handle repayments. Regardless of the manufacturer's process or its decisions regarding repayment, the Covered Entity is responsible for submitting a summary of its corrective actions and repayments to HHS for compliance and audit purposes.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions